Literature DB >> 30580919

Fatty Acids Compete with Aβ in Binding to Serum Albumin by Quenching Its Conformational Flexibility.

Cong Guo1, Huan-Xiang Zhou2.   

Abstract

Human serum albumin (HSA) has been identified as an important regulator of amyloid-β (Aβ) fibrillization both in blood plasma and in cerebrospinal fluid. Fatty acids bind to HSA, and high serum levels of fatty acids increase the risk of Alzheimer's disease. In vitro, fatty-acid-loaded HSA (FA·HSA) loses the protective effect against Aβ fibrillization, but the mechanism underlying the interference of fatty acids on Aβ-HSA interactions has been unclear. Here, we used molecular dynamics simulations to gain atomic-level insight on the weak binding of monomeric Aβ40 and Aβ42 peptides with apo and FA·HSA. Consistent with recent NMR data, C-terminal residues of the Aβ peptides have the highest propensities for interacting with apo HSA. Interestingly, the Aβ binding residues of apo and FA·HSA exhibit distinct patterns, which qualitatively correlate with backbone flexibility. In FA·HSA, both flexibilities and Aβ binding propensities are relatively even among the three domains. In contrast, in apo HSA, domain III shows the highest flexibility and is the primary target for Aβ binding. Specifically, deformation of apo HSA creates strong binding sites within subdomain IIIb, around the interface between subdomains IIIa and IIIb, and at the cleft between domains III and I. Therefore, much like disordered proteins, HSA can take advantage of flexibility in forming promiscuous interactions with partners, until the flexibility is quenched by fatty-acid binding. Our work explains the effect of fatty acids on Aβ-HSA binding and contributes to the understanding of HSA regulation of Aβ aggregation.
Copyright © 2018 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30580919      PMCID: PMC6349961          DOI: 10.1016/j.bpj.2018.11.3133

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  41 in total

1.  Application of fluoroimmunoassay to cerebrospinal fluid immunoglobulin G and albumin.

Authors:  R W Stevens; D Elmendorf; M Gourlay; E Stroebel; H A Gaafar
Journal:  J Clin Microbiol       Date:  1979-09       Impact factor: 5.948

2.  Molecular dynamics simulations of palmitate entry into the hydrophobic pocket of the fatty acid binding protein.

Authors:  Yossi Tsfadia; Ran Friedman; Jonathan Kadmon; Anna Selzer; Esther Nachliel; Menachem Gutman
Journal:  FEBS Lett       Date:  2007-02-28       Impact factor: 4.124

3.  Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Mary E Lame; Erin E Chambers; Matthew Blatnik
Journal:  Anal Biochem       Date:  2011-08-12       Impact factor: 3.365

4.  Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma.

Authors:  A L Biere; B Ostaszewski; E R Stimson; B T Hyman; J E Maggio; D J Selkoe
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

Review 5.  Protein folding, binding, and droplet formation in cell-like conditions.

Authors:  Sanbo Qin; Huan-Xiang Zhou
Journal:  Curr Opin Struct Biol       Date:  2016-10-20       Impact factor: 6.809

6.  Molecular Insights into Human Serum Albumin as a Receptor of Amyloid-β in the Extracellular Region.

Authors:  Tae Su Choi; Hyuck Jin Lee; Jong Yoon Han; Mi Hee Lim; Hugh I Kim
Journal:  J Am Chem Soc       Date:  2017-10-10       Impact factor: 15.419

7.  Therapeutic albumin binding to remove amyloid-β.

Authors:  Montserrat Costa; Ana M Ortiz; Juan I Jorquera
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 8.  Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization.

Authors:  Mercè Boada; Pilar Ortiz; Fernando Anaya; Isabel Hernández; Joan Muñoz; Laura Núñez; Javier Olazarán; Isabel Roca; Gemma Cuberas; Lluís Tárraga; Mar Buendia; Ramón P Pla; Isidre Ferrer; Antonio Páez
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

9.  Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.

Authors:  Mercè Boada; Fernando Anaya; Pilar Ortiz; Javier Olazarán; Joshua R Shua-Haim; Thomas O Obisesan; Isabel Hernández; Joan Muñoz; Mar Buendia; Montserrat Alegret; Asunción Lafuente; Lluís Tárraga; Laura Núñez; Mireia Torres; Joan Ramon Grifols; Isidre Ferrer; Oscar L Lopez; Antonio Páez
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: implications for Alzheimer disease.

Authors:  Helen F Stanyon; John H Viles
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

View more
  2 in total

1.  Sequence-Dependent Backbone Dynamics of Intrinsically Disordered Proteins.

Authors:  Souvik Dey; Matthew MacAinsh; Huan-Xiang Zhou
Journal:  J Chem Theory Comput       Date:  2022-09-09       Impact factor: 6.578

2.  Albumin in patients with liver disease shows an altered conformation.

Authors:  Margret Paar; Vera H Fengler; Daniel J Rosenberg; Angelika Krebs; Rudolf E Stauber; Karl Oettl; Michal Hammel
Journal:  Commun Biol       Date:  2021-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.